Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer

被引:76
作者
Duan, WR
Gao, L
Druhan, LJ
Zhu, WG
Morrison, C
Otterson, GA
Villalona-Calero, MA
机构
[1] Ohio State Univ, Coll Med & Publ Hlth, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med & Publ Hlth, Dept Internal Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Med & Publ Hlth, Dept Pathol, Columbus, OH 43210 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2004年 / 96卷 / 22期
关键词
D O I
10.1093/jnci/djh292
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Maintenance of p53 function is important for normal cell growth and development, and loss of p53 function contributes directly to malignant tumor development. The recently discovered Pirh2 protein is an ubiquitin-protein ligase that negatively regulates p53 through activity by targeting it for degradation. To determine how Pirh2 may mediate lung tumorigenesis, we evaluated Pirh2 expression in human and mouse lung tumor samples and paired normal lung tissues using immunoblot analysis and immunohistochemistry. Pirh2 protein expression was higher in 27 (84%) of 32 human lung neoplasms than in matched normal lung tissue and in 14 of 15 mouse lung tumors evaluated. In addition, p53 protein was more ubiquitinated in the mouse lung tumors than in normal tissue, and overall p53 expression was lower than that in normal tissue. These results are consistent with the hypothesis that increased Pirh2 expression affects lung tumorigenesis by reducing p53 activity. To our knowledge, this is the first description of altered Pirh2 expression in human and mouse tumors.
引用
收藏
页码:1718 / 1721
页数:4
相关论文
共 27 条
[1]  
Chen JD, 1996, MOL CELL BIOL, V16, P2445
[2]   RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model [J].
Duan, W ;
Ding, H ;
Zhu, WG ;
Srinivasan, K ;
Otterson, GA ;
Villalona-Calero, MA .
BIOTECHNIQUES, 2002, 33 (01) :58-+
[3]   Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice [J].
Duan, WR ;
Ding, HM ;
Subler, MA ;
Zhu, WG ;
Zhang, HM ;
Stoner, GD ;
Windle, JJ ;
Otterson, GA ;
Villalona-Calero, MA .
ONCOGENE, 2002, 21 (51) :7831-7838
[4]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[5]   WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO [J].
FARMER, G ;
BARGONETTI, J ;
ZHU, H ;
FRIEDMAN, P ;
PRYWES, R ;
PRIVES, C .
NATURE, 1992, 358 (6381) :83-86
[6]   Pharmacological rescue of mutant p53 conformation and function [J].
Foster, BA ;
Coffey, HA ;
Morin, MJ ;
Rastinejad, F .
SCIENCE, 1999, 286 (5449) :2507-2510
[7]   JNK targets p53 ubiquitination and degradation in nonstressed cells [J].
Fuchs, SY ;
Adler, V ;
Buschmann, T ;
Yin, ZM ;
Wu, XW ;
Jones, SN ;
Ronai, Z .
GENES & DEVELOPMENT, 1998, 12 (17) :2658-2663
[8]  
HARPER JW, 1993, CELL, V75, P805
[9]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[10]  
Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1